CA2447178C - Pharmaceutical composition for use in hormone replacement therapy - Google Patents

Pharmaceutical composition for use in hormone replacement therapy Download PDF

Info

Publication number: CA2447178C
Authority: CA; Canada
Prior art keywords: estrogenic; day; estrogenic component; use according; administration
Prior art date: 2001-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2447178A

Other languages

English (en)

French (fr)

Other versions

CA2447178A1 (en

Inventor

Christian Franz Holinka

Herman Jan Tijmen Coelingh Bennink

Evert Johannes Bunschoten

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Estetra SRL

Original Assignee

Pantarhei Bioscience BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-18

Filing date

2002-05-17

Publication date

2010-06-08

2001-05-18 Priority claimed from EP01201896A external-priority patent/EP1260225A1/de

2001-05-23 Priority claimed from EP01201945A external-priority patent/EP1293210B1/de

2001-08-31 Priority claimed from EP01203305A external-priority patent/EP1287817A1/de

2002-05-17 Application filed by Pantarhei Bioscience BV filed Critical Pantarhei Bioscience BV

2002-11-28 Publication of CA2447178A1 publication Critical patent/CA2447178A1/en

2010-06-08 Application granted granted Critical

2010-06-08 Publication of CA2447178C publication Critical patent/CA2447178C/en

2022-05-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000002657 hormone replacement therapy Methods 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title description 8
230000001076 estrogenic effect Effects 0.000 claims abstract description 122
238000000034 method Methods 0.000 claims abstract description 61
239000000203 mixture Substances 0.000 claims abstract description 47
239000000583 progesterone congener Substances 0.000 claims abstract description 37
239000000126 substance Substances 0.000 claims abstract description 29
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 16
238000012377 drug delivery Methods 0.000 claims abstract description 14
238000002560 therapeutic procedure Methods 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
230000000708 anti-progestin effect Effects 0.000 claims abstract description 6
239000003418 antiprogestin Substances 0.000 claims abstract description 6
238000007911 parenteral administration Methods 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 35
-1 inhalers Substances 0.000 claims description 17
210000002966 serum Anatomy 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 11
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 10
229940088597 hormone Drugs 0.000 claims description 10
239000005556 hormone Substances 0.000 claims description 10
238000007920 subcutaneous administration Methods 0.000 claims description 10
108700012941 GNRH1 Proteins 0.000 claims description 9
208000024891 symptom Diseases 0.000 claims description 8
208000001132 Osteoporosis Diseases 0.000 claims description 7
239000000074 antisense oligonucleotide Substances 0.000 claims description 6
238000012230 antisense oligonucleotides Methods 0.000 claims description 6
230000002685 pulmonary effect Effects 0.000 claims description 6
206010027304 Menopausal symptoms Diseases 0.000 claims description 5
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 5
108091034117 Oligonucleotide Proteins 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 4
230000000295 complement effect Effects 0.000 claims description 4
239000003405 delayed action preparation Substances 0.000 claims description 4
229930195733 hydrocarbon Natural products 0.000 claims description 4
239000002773 nucleotide Substances 0.000 claims description 4
125000003729 nucleotide group Chemical group 0.000 claims description 4
230000037317 transdermal delivery Effects 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 3
239000004215 Carbon black (E152) Substances 0.000 claims description 3
206010058359 Hypogonadism Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
206010033165 Ovarian failure Diseases 0.000 claims description 3
208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
208000010877 cognitive disease Diseases 0.000 claims description 3
150000002430 hydrocarbons Chemical class 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
208000016685 primary ovarian failure Diseases 0.000 claims description 3
239000003488 releasing hormone Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
108010060374 FSH Receptors Proteins 0.000 claims description 2
102000006771 Gonadotropins Human genes 0.000 claims description 2
108010086677 Gonadotropins Proteins 0.000 claims description 2
239000002622 gonadotropin Substances 0.000 claims description 2
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 2
239000007922 nasal spray Substances 0.000 claims description 2
XEZQLSOFXLPSJR-UHFFFAOYSA-N oxane-2-carbaldehyde Chemical compound O=CC1CCCCO1 XEZQLSOFXLPSJR-UHFFFAOYSA-N 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
208000017657 Menopausal disease Diseases 0.000 claims 2
102000018343 Follicle stimulating hormone receptors Human genes 0.000 claims 1
239000002243 precursor Substances 0.000 abstract description 15
239000000262 estrogen Substances 0.000 description 95
229940011871 estrogen Drugs 0.000 description 93
AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 description 82
239000000306 component Substances 0.000 description 75
241000700159 Rattus Species 0.000 description 64
229950009589 estetrol Drugs 0.000 description 60
239000003981 vehicle Substances 0.000 description 47
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 34
229940079593 drug Drugs 0.000 description 33
239000003814 drug Substances 0.000 description 33
102000015694 estrogen receptors Human genes 0.000 description 33
108010038795 estrogen receptors Proteins 0.000 description 33
229960005309 estradiol Drugs 0.000 description 32
229940106582 estrogenic substances Drugs 0.000 description 31
230000000694 effects Effects 0.000 description 27
150000003431 steroids Chemical class 0.000 description 27
230000006003 cornification Effects 0.000 description 23
230000004044 response Effects 0.000 description 23
241001465754 Metazoa Species 0.000 description 22
241000282414 Homo sapiens Species 0.000 description 21
239000010410 layer Substances 0.000 description 21
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 20
230000027455 binding Effects 0.000 description 20
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 18
102100038595 Estrogen receptor Human genes 0.000 description 17
230000000035 biogenic effect Effects 0.000 description 16
210000000988 bone and bone Anatomy 0.000 description 16
239000003446 ligand Substances 0.000 description 16
239000000853 adhesive Substances 0.000 description 15
230000001070 adhesive effect Effects 0.000 description 15
229960002568 ethinylestradiol Drugs 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
206010060800 Hot flush Diseases 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
238000012360 testing method Methods 0.000 description 13
229930182833 estradiol Natural products 0.000 description 12
239000000463 material Substances 0.000 description 12
239000002344 surface layer Substances 0.000 description 12
230000002357 endometrial effect Effects 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 10
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 10
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 10
101000703436 Homo sapiens Sex hormone-binding globulin Proteins 0.000 description 10
230000008901 benefit Effects 0.000 description 10
238000004166 bioassay Methods 0.000 description 10
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 10
102000048863 human SHBG Human genes 0.000 description 10
229910052500 inorganic mineral Inorganic materials 0.000 description 10
239000011707 mineral Substances 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 9
102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 9
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 9
210000004696 endometrium Anatomy 0.000 description 9
229960001348 estriol Drugs 0.000 description 9
238000009472 formulation Methods 0.000 description 9
229960005181 morphine Drugs 0.000 description 9
229960004127 naloxone Drugs 0.000 description 9
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 9
239000008159 sesame oil Substances 0.000 description 9
235000011803 sesame oil Nutrition 0.000 description 9
239000003826 tablet Substances 0.000 description 9
230000001836 utereotrophic effect Effects 0.000 description 9
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 8
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
238000011121 vaginal smear Methods 0.000 description 8
206010030247 Oestrogen deficiency Diseases 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000012790 adhesive layer Substances 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
239000000333 selective estrogen receptor modulator Substances 0.000 description 7
229940095743 selective estrogen receptor modulator Drugs 0.000 description 7
210000002303 tibia Anatomy 0.000 description 7
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
230000007423 decrease Effects 0.000 description 6
229920001971 elastomer Polymers 0.000 description 6
210000002919 epithelial cell Anatomy 0.000 description 6
239000003687 estradiol congener Substances 0.000 description 6
229940028334 follicle stimulating hormone Drugs 0.000 description 6
230000002440 hepatic effect Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
238000009806 oophorectomy Methods 0.000 description 6
210000001672 ovary Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
210000004291 uterus Anatomy 0.000 description 6
IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000013461 design Methods 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
230000003054 hormonal effect Effects 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
230000002611 ovarian Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
239000003961 penetration enhancing agent Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 4
241000283073 Equus caballus Species 0.000 description 4
238000011887 Necropsy Methods 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
239000002775 capsule Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000000806 elastomer Substances 0.000 description 4
229960003399 estrone Drugs 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 4
229960001390 mestranol Drugs 0.000 description 4
229940127240 opiate Drugs 0.000 description 4
238000003305 oral gavage Methods 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000013641 positive control Substances 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000013223 sprague-dawley female rat Methods 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
229960003604 testosterone Drugs 0.000 description 4
210000000689 upper leg Anatomy 0.000 description 4
239000006213 vaginal ring Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000001548 androgenic effect Effects 0.000 description 3
229960003473 androstanolone Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000000123 anti-resoprtive effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037118 bone strength Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000036757 core body temperature Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
238000009164 estrogen replacement therapy Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000003304 gavage Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003780 keratinization Effects 0.000 description 3
229960003299 ketamine Drugs 0.000 description 3
229940040129 luteinizing hormone Drugs 0.000 description 3
230000036651 mood Effects 0.000 description 3
229940094984 other estrogen in atc Drugs 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
239000008299 semisolid dosage form Substances 0.000 description 3
229920002379 silicone rubber Polymers 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
229910052722 tritium Inorganic materials 0.000 description 3
238000005406 washing Methods 0.000 description 3
RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 description 2
JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 description 2
206010000060 Abdominal distension Diseases 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
206010006298 Breast pain Diseases 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000006662 Mastodynia Diseases 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
206010027514 Metrorrhagia Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
206010067572 Oestrogenic effect Diseases 0.000 description 2
206010033557 Palpitations Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003098 androgen Substances 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229940050390 benzoate Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
208000024330 bloating Diseases 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
201000001883 cholelithiasis Diseases 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000003433 contraceptive agent Substances 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
238000000326 densiometry Methods 0.000 description 2
229960000452 diethylstilbestrol Drugs 0.000 description 2
230000008406 drug-drug interaction Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000003195 fascia Anatomy 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000007373 indentation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
201000010260 leiomyoma Diseases 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229950001701 lilopristone Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004705 lumbosacral region Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
208000007106 menorrhagia Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000003228 microsomal effect Effects 0.000 description 2
229940100652 nasal gel Drugs 0.000 description 2
229940100656 nasal solution Drugs 0.000 description 2
230000008693 nausea Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000005060 rubber Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000003303 sex hormone antagonist Substances 0.000 description 2
229920000260 silastic Polymers 0.000 description 2
239000004945 silicone rubber Substances 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
229940044953 vaginal ring Drugs 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
BWDBEAQIHAEVLV-UHFFFAOYSA-N 6-methylheptan-1-ol Chemical compound CC(C)CCCCCO BWDBEAQIHAEVLV-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
230000035502 ADME Effects 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
208000005641 Adenomyosis Diseases 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
206010005746 Blood pressure fluctuation Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
206010006313 Breast tenderness Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
101710116773 Corticosteroid-binding globulin Proteins 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
102100027819 Cytosolic beta-glucosidase Human genes 0.000 description 1
241001414597 Destria Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
229940127406 Estrogen Receptor Agonists Drugs 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010016807 Fluid retention Diseases 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920002821 Modacrylic Polymers 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
101100281518 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fox-2 gene Proteins 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000005062 Polybutadiene Substances 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
229920000081 Polyestradiol phosphate Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920001328 Polyvinylidene chloride Polymers 0.000 description 1
229920003080 Povidone K 25 Polymers 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
229920001807 Urea-formaldehyde Polymers 0.000 description 1
206010071018 Urogenital atrophy Diseases 0.000 description 1
206010046764 Uterine atrophy Diseases 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
206010046910 Vaginal haemorrhage Diseases 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
238000001801 Z-test Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000003869 acetamides Chemical class 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000002365 anti-tubercular Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
238000005899 aromatization reaction Methods 0.000 description 1
150000005840 aryl radicals Chemical group 0.000 description 1
238000013096 assay test Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
KVBYPTUGEKVEIJ-UHFFFAOYSA-N benzene-1,3-diol;formaldehyde Chemical compound O=C.OC1=CC=CC(O)=C1 KVBYPTUGEKVEIJ-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000005961 cardioprotection Effects 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000003915 cell function Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
239000000039 congener Substances 0.000 description 1
229940035811 conjugated estrogen Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical class CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000466 effect on haemostasis Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000005168 endometrial cell Anatomy 0.000 description 1
201000009274 endometriosis of uterus Diseases 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960005416 estradiol cypionate Drugs 0.000 description 1
229960004766 estradiol valerate Drugs 0.000 description 1
150000002159 estradiols Chemical class 0.000 description 1
229950008385 estrone sulphate Drugs 0.000 description 1
229940081345 estropipate Drugs 0.000 description 1
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
229960002767 ethosuximide Drugs 0.000 description 1
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
150000004673 fluoride salts Chemical class 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000000622 liquid--liquid extraction Methods 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
XFHJDMUEHUHAJW-UHFFFAOYSA-N n-tert-butylprop-2-enamide Chemical compound CC(C)(C)NC(=O)C=C XFHJDMUEHUHAJW-UHFFFAOYSA-N 0.000 description 1
229940100657 nasal ointment Drugs 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000012316 non-parametric ANOVA Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
108091008589 nuclear estrogen receptors Proteins 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
229920001568 phenolic resin Polymers 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920001084 poly(chloroprene) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920002857 polybutadiene Polymers 0.000 description 1
229920001083 polybutene Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229960001298 polyestradiol phosphate Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001195 polyisoprene Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920003225 polyurethane elastomer Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920001289 polyvinyl ether Polymers 0.000 description 1
239000005033 polyvinylidene chloride Substances 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
229960002393 primidone Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
229960001424 quinestrol Drugs 0.000 description 1
PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000009834 selective interaction Effects 0.000 description 1
238000011452 sequencing regimen Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229920003048 styrene butadiene rubber Polymers 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
231100001042 uterine atrophy Toxicity 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

CA2447178A 2001-05-18 2002-05-17 Pharmaceutical composition for use in hormone replacement therapy Expired - Lifetime CA2447178C (en)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
EP01201896A EP1260225A1 (de)	2001-05-18	2001-05-18	Pharmazeutische Zusammensetzung für die Hormonersatztherapie
EP01201896.6		2001-05-18
EP01201946.9		2001-05-23
EP01201947.7		2001-05-23
EP01201947		2001-05-23
EP01201946		2001-05-23
EP01201945A EP1293210B1 (de)	2001-05-23	2001-05-23	Zubereitungen für die hormonale Kontrazeption
EP01201945.1		2001-05-23
EP01203305A EP1287817A1 (de)	2001-08-31	2001-08-31	Verfahren und intravaginales Arzneiverabreichungsvorrichtung zur Behandlung von uterinem Myom
EP01203305.6		2001-08-31
EP01204377.4		2001-11-15
EP01204377		2001-11-15
EP02075695.3		2002-02-21
EP02075695		2002-02-21
PCT/NL2002/000317 WO2002094276A1 (en)	2001-05-18	2002-05-17	Pharmaceutical composition for use in hormone replacement therapy

Publications (2)

Publication Number	Publication Date
CA2447178A1 CA2447178A1 (en)	2002-11-28
CA2447178C true CA2447178C (en)	2010-06-08

Family

ID=27561854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2447178A Expired - Lifetime CA2447178C (en)	2001-05-18	2002-05-17	Pharmaceutical composition for use in hormone replacement therapy

Country Status (10)

Country	Link
US (1)	US8048869B2 (de)
EP (1)	EP1390040B1 (de)
AT (1)	ATE350041T1 (de)
CA (1)	CA2447178C (de)
CY (1)	CY1106457T1 (de)
DE (1)	DE60217324T2 (de)
DK (1)	DK1390040T3 (de)
ES (1)	ES2278924T3 (de)
PT (1)	PT1390040E (de)
WO (1)	WO2002094276A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040214807A1 (en) *	1993-08-06	2004-10-28	D'amato Robert J.	Estrogenic compounds as anti-mitotic agents
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
US20050192258A1 (en) *	2000-08-18	2005-09-01	Agoston Gregory E.	Antiangiogenic agents
US20050096283A1 (en) *	2001-12-14	2005-05-05	The Regents Of University Of California	Methods of inhibiting fertility
EP1526856B1 (de)	2002-07-12	2008-01-02	Pantarhei Bioscience B.V.	Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US8987240B2 (en)	2002-10-23	2015-03-24	Pantarhei Bioscience B.V.	Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU2003279624A1 (en)	2002-11-08	2004-06-07	Pantarhei Bioscience B.V.	Synthesis of estetrol via estrone derived steroids
JP2006526025A (ja) *	2003-05-28	2006-11-16	エントレメッドインコーポレイテッド	抗血管新生剤
US20070004689A1 (en) *	2004-03-12	2007-01-04	Agoston Gregory E	Antiangiogenic agents
CA2558014A1 (en) *	2004-03-12	2005-09-29	Entremed, Inc.	Antiangiogenic agents
DE102004026671A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) *	2004-05-28	2005-12-15	Grünenthal GmbH	Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US20060116360A1 (en) *	2004-11-29	2006-06-01	Fogler William E	Method of administering anti-angiogenic agents and a method of treating disease using same
US20070185069A1 (en) *	2005-11-14	2007-08-09	Plum Stacy M	Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
JP2009530388A (ja)	2006-03-20	2009-08-27	エントレメッドインコーポレイテッド	２−メトキシエストラジオールの疾患修飾性抗関節炎活性
WO2007118205A2 (en) *	2006-04-07	2007-10-18	University Of Maryland, Baltimore	Compounds, compositions and methods for treating hormone-dependent maladies
US20100087407A1 (en) *	2006-08-04	2010-04-08	James Symons	use of aromatase inhibitors
WO2008094665A1 (en) *	2007-01-31	2008-08-07	Entremed, Inc.	Method of treating amyloidosis mediated diseases
US20080293683A1 (en) *	2007-05-24	2008-11-27	University Of Kansas Medical Center	Hormone Replacement Therapy
WO2009075838A2 (en) *	2007-12-10	2009-06-18	Meditrina Pharmaceuticals, Inc.	Treatment of menorrhagia with aromatase inhibitor
EA025511B1 (ru)	2011-06-01	2016-12-30	Эстетра С.П.Р.Л.	Способ получения промежуточных соединений эстетрола
CN103703014A (zh)	2011-06-01	2014-04-02	埃斯特拉公司	用于产生雌四醇中间体的方法
EP2383279A1 (de)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Herstellungsverfahren für Esterol
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
WO2013034780A2 (en)	2012-12-20	2013-03-14	Crystal Pharma, S.A.U.	Process for the preparation of estetrol and related compounds
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US9988417B2 (en)	2013-09-18	2018-06-05	Crystal Pharma, S.A.U.	Process for the preparation of estetrol
JP6447931B2 (ja) *	2013-12-12	2019-01-09	ドネスタバイオサイエンスビー．ブイ．ＤｏｎｅｓｔａＢｉｏｓｃｉｅｎｃｅＢ．Ｖ．	エステトロール成分を含有する口腔内崩壊固体単位剤形
CA2947767A1 (en)	2014-05-22	2015-11-26	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
PL3310345T3 (pl)	2015-06-18	2021-10-18	Estetra Sprl	Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
JP6813150B2 (ja)	2015-06-18	2021-01-13	エステトラソシエテプリーヴアレスポンサビリテリミテ	エステトロールを含有する口腔内崩壊錠
ES2671160T3 (es)	2015-06-18	2018-06-05	Mithra Pharmaceuticals S.A.	Unidad de dosificación orodispersable que contiene un componente estetrol
LT3701944T (lt)	2015-06-18	2022-04-11	Estetra Srl	Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
KR102712911B1 (ko)	2016-08-05	2024-10-04	에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼	월경통 및 생리통의 관리방법
SG11202009725XA (en)	2018-04-19	2020-11-27	Estetra Sprl	Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu)	2019-09-03	2022-04-28	Richter Gedeon Nyrt.	Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物
HUP2400151A1 (hu)	2024-02-28	2025-09-28	Richter Gedeon Nyrt	Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3440320A (en) *	1964-06-18	1969-04-22	Mortimer D Sackler	Chelated suppository and method of using same
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) *	1973-07-13	1975-04-03	Schering Ag	1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) *	1973-07-13	1975-04-17	Schering Ag	1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) *	1974-05-31	1975-12-18	Schering Ag	1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) *	1978-06-07	1988-02-02	Kali-Chemie Pharma Gmbh	Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) *	1981-02-17	1984-07-17	Alza Corporation	Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) *	1984-01-03	1986-03-04	Jonergin, Inc.	Device for the administration of an active agent to the skin or mucosa
US4624665A (en) *	1984-10-01	1986-11-25	Biotek, Inc.	Method of transdermal drug delivery
US4937238A (en) *	1986-03-04	1990-06-26	The Board Of Regents Of The University Of Nebraska	Prevention of mammary carcinoma
US4762717A (en) *	1986-03-21	1988-08-09	The General Hospital Corporation	Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) *	1988-02-26	1993-06-29	Riker Laboratories, Inc.	Transdermal estradiol delivery system
US5043331A (en)	1989-06-15	1991-08-27	Orion-Yhtyma Oy	Treatment of postmenopausal disorders
US5130137A (en) *	1989-08-09	1992-07-14	The General Hospital Corporation	Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja)	1990-07-26	1992-08-24	Sumitomo Chem Co Ltd	スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) *	1990-09-14	1991-11-05	Plains Cotton Cooperative Association	Goods database employing electronic title or documentary-type title
US5340585A (en)	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
US5340586A (en) *	1991-04-12	1994-08-23	University Of Southern California	Methods and formulations for use in treating oophorectomized women
US5211952A (en)	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
US5468736A (en) *	1993-02-25	1995-11-21	The Medical College Of Hampton Road	Hormone replacement therapy
US5895783A (en)	1993-07-16	1999-04-20	Schering Aktiengesellschaft	Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) *	1993-09-09	1995-04-03	Saturnus Ag	Preparaat voor substitutietherapie.
DE4344405C2 (de)	1993-12-24	1995-12-07	Marika Dr Med Ehrlich	Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) *	1994-08-04	1996-02-15	Biex, Inc.	Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) *	1994-08-12	1996-02-01	Jenapharm Gmbh	Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
WO1998058657A1 (en)	1997-06-20	1998-12-30	Akzo Nobel N.V.	Gonadotropin releasing hormone antagonist
DE19739916C2 (de) *	1997-09-11	2001-09-13	Hesch Rolf Dieter	Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) *	1998-12-23	2001-04-10	Ortho-Mcneil Pharmaceuticals, Inc.	Triphasic oral contraceptive
DE19917930A1 (de)	1999-04-15	2000-10-19	Schering Ag	Ent-Steroide als selektiv wirksame Estrogene
AU4543200A (en)	1999-04-16	2000-11-02	Dittgen, Michael	Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
WO2000073416A1 (en)	1999-05-28	2000-12-07	University Of Cincinnati	Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
AU5984701A (en)	2000-05-12	2001-11-20	Univ Oregon Health & Science	Method of treating immune pathologies with low dose estrogen
US6936599B2 (en) *	2001-04-25	2005-08-30	The Regents Of The University Of California	Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (de)	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	Pharmazeutische Zusammensetzung für die Hormonersatztherapie

2002
- 2002-05-17 AT AT02738951T patent/ATE350041T1/de active
- 2002-05-17 DK DK02738951T patent/DK1390040T3/da active
- 2002-05-17 WO PCT/NL2002/000317 patent/WO2002094276A1/en not_active Ceased
- 2002-05-17 DE DE60217324T patent/DE60217324T2/de not_active Expired - Lifetime
- 2002-05-17 CA CA2447178A patent/CA2447178C/en not_active Expired - Lifetime
- 2002-05-17 PT PT02738951T patent/PT1390040E/pt unknown
- 2002-05-17 ES ES02738951T patent/ES2278924T3/es not_active Expired - Lifetime
- 2002-05-17 US US10/478,262 patent/US8048869B2/en not_active Expired - Lifetime
- 2002-05-17 EP EP02738951A patent/EP1390040B1/de not_active Expired - Lifetime
2007
- 2007-03-22 CY CY20071100403T patent/CY1106457T1/el unknown

Also Published As

Publication number	Publication date
ATE350041T1 (de)	2007-01-15
US8048869B2 (en)	2011-11-01
EP1390040B1 (de)	2007-01-03
PT1390040E (pt)	2007-04-30
US20040198671A1 (en)	2004-10-07
EP1390040A1 (de)	2004-02-25
ES2278924T3 (es)	2007-08-16
DK1390040T3 (da)	2007-04-23
CA2447178A1 (en)	2002-11-28
CY1106457T1 (el)	2011-10-12
DE60217324D1 (de)	2007-02-15
DE60217324T2 (de)	2007-04-26
WO2002094276A1 (en)	2002-11-28

Legal Events

Date	Code	Title	Description
2007-04-16	EEER	Examination request
2022-07-19	MKEX	Expiry	Effective date: 20220517

Publication	Publication Date	Title
CA2447178C (en)	2010-06-08	Pharmaceutical composition for use in hormone replacement therapy
EP1700602A1 (de)	2006-09-13	Pharmaceutishe Zusammensetzung für die Hormonersatztherapie
CA2467222C (en)	2010-06-08	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CA2448273C (en)	2010-06-29	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US7732430B2 (en)	2010-06-08	Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
JP6012048B2 (ja)	2016-10-25	アロマターゼ阻害剤およびゲスターゲンを放出する、子宮内膜症を処置するための非経口用剤形
WO2003018026A1 (en)	2003-03-06	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US20060063723A1 (en)	2006-03-23	Pharmaceutical composition comprising esterol derivatives for use in cancer therapy
JP6486900B2 (ja)	2019-03-20	プロゲステロン受容体アンタゴニスト剤形
WO2003103683A1 (en)	2003-12-18	Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis
KR100729311B1 (ko)	2007-06-19	호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질)